Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Healthcare Biotechnology
Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Trillium Therapeutics Inc. > TRIL at $1.30US, fair value estimate is $24.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(17)
•••
Comment by cpacon Jan 09, 2020 9:04am
221 Views
Post# 30533821

RE:RE:TRIL at $1.30US, fair value estimate is $24.

RE:RE:TRIL at $1.30US, fair value estimate is $24.Don't take my word for it; that comes from Bloom Burton... a broker that I have a ton of respect for...

Think about it though... FTSV a company that's so 'all in' on the CD47 concept that they named the company Forty Seven, lol  is valued at $1.5B USD... they are slightly further ahead in their trials, but our molecules are decidedly superior...  So they might be first in class, but we are best in class... wouldn't big pharma be willing to wait a little long for a CD47 option that didn't teach Macrophages to eat red blood cells along with the tumor cells?

Cheers,
CPAC
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities